SBIR Phase I: Technology development and pre-clinical testing of a novel minimally invasive catheter-based blood clot-retrieval and clot-filtering device

SBIR 第一阶段：新型微创导管血凝块回收和凝块过滤装置的技术开发和临床前测试

• 批准号: 0946099
• 负责人: Vallabh Janardhan
• 金额: $ 15万
• 依托单位: Insera Therapeutics Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0946099&HistoricalAwards=false
• 关键词: SBIR; Phase; Technology; development; pre

This Small Business Innovation Research (SBIR) Phase I project aims to develop the industry's first catheter-based stroke treatment device that serves both as a blood clot-retrieval as well as a clot-filtering device. Stroke is a major economic burden on the tax payer costing $65.5 billion/year. The mean lifetime healthcare cost for a stroke patient is $140,048. The first step in the treatment of acute stroke is the removal of the blood clot to restore vital blood supply to the brain. However, existing catheter-based therapies have only shown modest success in removing clots and are effective in less than two-thirds of stroke patients. In addition, these therapies can release debris into the blood stream causing further strokes. The research objective of this project is to perform pre-clinical testing of a more effective clot-retrieval device and a clot-filtering device that can make existing stroke therapies safer.The broader impacts of this research are far-reaching as the global stroke burden is staggering. Each year 780,000 strokes occur in the US and nearly 20.5 million strokes occur worldwide. This project is projected to yield important outcomes. First, the efficacy of this clot-retrieval device in removing blood clots will be confirmed. Second, the efficacy of this clot-filtering device will be confirmed in preventing release of debris during catheter-based stroke treatments thereby making these procedures safer. This public-private partnership is expected to have an important positive impact on the community by saving lives, creating jobs, and decreasing the economic burden of stroke on the tax payer.

该小型企业创新研究 (SBIR) 第一阶段项目旨在开发业界首款基于导管的中风治疗设备，该设备既可用作血块回收设备，也可用作血块过滤设备。中风是纳税人的一项重大经济负担，每年造成 655 亿美元的损失。中风患者的平均终生医疗费用为 140,048 美元。治疗急性中风的第一步是去除血块以恢复大脑的重要血液供应。然而，现有的基于导管的疗法在清除血栓方面仅取得了一定的成功，并且对不到三分之二的中风患者有效。此外，这些疗法可能会将碎片释放到血流中，导致进一步的中风。该项目的研究目标是对更有效的血栓回收装置和血栓过滤装置进行临床前测试，使现有的中风治疗更加安全。随着全球中风负担令人震惊，这项研究的更广泛影响是深远的。美国每年发生 780,000 例中风，全球发生近 2050 万例中风。该项目预计将产生重要成果。首先，将确认该血栓回收装置去除血栓的功效。其次，这种凝块过滤装置在防止基于导管的中风治疗期间碎片释放方面的功效将得到证实，从而使这些手术更加安全。这种公私合作伙伴关系预计将通过拯救生命、创造就业机会和减轻纳税人的中风经济负担对社区产生重要的积极影响。